Literature DB >> 8112293

Association of p56lck with the cytoplasmic domain of CD4 modulates HIV-1 expression.

M Tremblay1, S Meloche, S Gratton, M A Wainberg, R P Sékaly.   

Abstract

To investigate the role played by the cytoplasmic domain of the CD4 glycoprotein in the process of HIV infection, we have transfected two CD4-negative human T cell lines with cDNAs encoding the full-length CD4 and a truncated form of the molecule, lacking most of the cytoplasmic domain. Levels of viral replication were significantly higher in cells carrying the truncated version of CD4, in comparison with cells expressing the full-length CD4, as measured by the percentage of cells expressing viral p24 protein and the number of infectious particles released into culture supernatants. The extent of viral entry and reverse transcription was similar in each case, as monitored by an enzymatic test and quantitative PCR. Quantitative differences at RNA and protein levels were responsible for changes in viral production. To further characterize the mechanisms responsible for decreased rates of HIV replication in CD4-expressing cells we have treated the different cell lines, very early after HIV infection, with azidothymidine and soluble CD4, two antiviral agents that inhibit replication of HIV at different stages in the virus replicative cycle. Results from these experiments indicate that a cellular signal is mediated by the CD4 molecule, which negatively regulates the expression of viral DNA already present in such cells. This signal would be initiated following oligomerization of the CD4 molecule by the virus itself. Results from experiments with a CD4 construct containing mutations of the cysteine residues which are responsible for association of CD4 with p56lck demonstrate that p56lck is implicated in the transduction of the signal negatively regulating HIV replication.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8112293      PMCID: PMC394876          DOI: 10.1002/j.1460-2075.1994.tb06320.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  61 in total

1.  Viral DNA carried by human immunodeficiency virus type 1 virions.

Authors:  F Lori; F di Marzo Veronese; A L de Vico; P Lusso; M S Reitz; R C Gallo
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Association of tyrosine kinase p56lck with CD4 inhibits the induction of growth through the alpha beta T-cell receptor.

Authors:  L Haughn; S Gratton; L Caron; R P Sékaly; A Veillette; M Julius
Journal:  Nature       Date:  1992-07-23       Impact factor: 49.962

3.  Human immunodeficiency virus gp120 and derived peptides activate protein tyrosine kinase p56lck in human CD4 T lymphocytes.

Authors:  C Hivroz; F Mazerolles; M Soula; R Fagard; S Graton; S Meloche; R P Sekaly; A Fischer
Journal:  Eur J Immunol       Date:  1993-03       Impact factor: 5.532

4.  A human binding site for transcription factor USF/MLTF mimics the negative regulatory element of human immunodeficiency virus type 1.

Authors:  M Giacca; M I Gutierrez; S Menzo; F d'Adda di Fagagna; A Falaschi
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

5.  An assay for quantifying infectious HIV particles.

Authors:  E Tjøtta; O Hungnes; B Grinde
Journal:  J Virol Methods       Date:  1990-02       Impact factor: 2.014

6.  Inhibition of virus production in peripheral blood mononuclear cells from human immunodeficiency virus (HIV) type 1-seropositive donors by treatment with recombinant HIV-like particles.

Authors:  O K Haffar; P A Moran; M D Smithgall; M L Diegel; P Sridhar; J A Ledbetter; J M Zarling; S L Hu
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

7.  The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck.

Authors:  A Veillette; M A Bookman; E M Horak; J B Bolen
Journal:  Cell       Date:  1988-10-21       Impact factor: 41.582

8.  Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses.

Authors:  D Trono
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

9.  High level of surface CD4 prevents stable human immunodeficiency virus infection of T-cell transfectants.

Authors:  W L Marshall; D C Diamond; M M Kowalski; R W Finberg
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

10.  Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis.

Authors:  N K Banda; J Bernier; D K Kurahara; R Kurrle; N Haigwood; R P Sekaly; T H Finkel
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more
  21 in total

1.  Upregulation of human immunodeficiency virus (HIV) replication by CD4 cross-linking in peripheral blood mononuclear cells of HIV-infected adults.

Authors:  S Than; N Oyaizu; S Tetali; J Romano; M Kaplan; S Pahwa
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD).

Authors:  T Idziorek; J Khalife; O Billaut-Mulot; E Hermann; M Aumercier; Y Mouton; A Capron; G M Bahr
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

3.  Binding of human immunodeficiency virus type 1 to CD4 induces association of Lck and Raf-1 and activates Raf-1 by a Ras-independent pathway.

Authors:  W Popik; P M Pitha
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

4.  Segregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virus.

Authors:  Susan L Kozak; Jean Michel Heard; David Kabat
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Glycosyl-phosphatidylinositol-anchored and transmembrane forms of CD46 display similar measles virus receptor properties: virus binding, fusion, and replication; down-regulation by hemagglutinin; and virus uptake and endocytosis for antigen presentation by major histocompatibility complex class II molecules.

Authors:  G Varior-Krishnan; M C Trescol-Biémont; D Naniche; C Rabourdin-Combe; D Gerlier
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4.

Authors:  M Benkirane; H Schmid-Antomarchi; D R Littman; M Hirn; B Rossi; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 7.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

8.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

Review 9.  HIV: cell binding and entry.

Authors:  Craig B Wilen; John C Tilton; Robert W Doms
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.

Authors:  Richard D Sloan; Daniel A Donahue; Björn D Kuhl; Tamara Bar-Magen; Mark A Wainberg
Journal:  Retrovirology       Date:  2010-05-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.